Liminatus Pharma, Inc.
LIMN
$3.84
$0.205.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1,097.94% | -184.04% | -187.81% | 44.53% | 77.65% |
| Total Depreciation and Amortization | 185.71% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 770.94% | -- | -- | -- | -- |
| Change in Net Operating Assets | 100.45% | -455.63% | -433.33% | -396.35% | -371.03% |
| Cash from Operations | 57.39% | -633.88% | -586.60% | -496.37% | -345.57% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | 94.16% | 72.81% | 52.15% | 8.37% |
| Cash from Investing | 99.38% | 93.78% | 77.80% | 61.43% | 29.61% |
| Total Debt Issued | -100.00% | -21.76% | 10.63% | 9.02% | 32.49% |
| Total Debt Repaid | -- | -- | -- | 100.00% | -- |
| Issuance of Common Stock | -63.98% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 148.64% | -- | -- | -- | -10,532.50% |
| Cash from Financing | -55.58% | 199.94% | 116.88% | 110.00% | 135.36% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 28.74% | 568.79% | 135.80% | 276.71% | 330.69% |